Nkarta (NKTX) Equity Average (2019 - 2026)
Nkarta's quarterly Equity Average came in at $299.1 million in Q1 2026, down 23.97% year-on-year from $393.4 million in Q1 2025, and down 8.0% quarter-over-quarter from $325.1 million in Q4 2025.
Nkarta has reported Equity Average for 8 years, with the latest figure at $299.1 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 23.97% year-over-year to $299.1 million; the trailing twelve-month figure through Mar 2026 stood at $299.1 million (down 23.97% YoY), and the FY2025 full-year result was $360.2 million, up 5.73% from the prior year.
- Equity Average for Q1 2026 stood at $299.1 million, down from $325.1 million in the prior quarter.
- The five-year high for Equity Average was $463.4 million in Q2 2024, with the low at $239.8 million in Q1 2022.
- Average Equity Average over 5 years is $357.5 million, with a median of $359.4 million recorded in 2023.
- Peak annual rise in Equity Average reached 49.86% in 2023, while the deepest fall reached 26.1% in 2023.
- Tracing NKTX's Equity Average over 5 years: stood at $385.7 million in 2022, then retreated by 26.1% to $285.1 million in 2023, then soared by 47.14% to $419.4 million in 2024, then slipped by 22.49% to $325.1 million in 2025, then retreated by 8.0% to $299.1 million in 2026.
- The last three Equity Average figures came in at $299.1 million (Q1 2026), $325.1 million (Q4 2025), and $347.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 299.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 299.09 Mn |
| Dec 31, 2025 | 325.11 Mn |
| Sep 30, 2025 | 347.78 Mn |
| Jun 30, 2025 | 368.24 Mn |
| Mar 31, 2025 | 393.39 Mn |
| Dec 31, 2024 | 419.42 Mn |
| Sep 30, 2024 | 442.03 Mn |
| Jun 30, 2024 | 463.42 Mn |
| Mar 31, 2024 | 373.47 Mn |
| Dec 31, 2023 | 285.05 Mn |
| Sep 30, 2023 | 307.40 Mn |
| Jun 30, 2023 | 332.31 Mn |
| Mar 31, 2023 | 359.43 Mn |
| Dec 31, 2022 | 385.74 Mn |
| Sep 30, 2022 | 410.15 Mn |
| Jun 30, 2022 | 324.87 Mn |
| Mar 31, 2022 | 239.84 Mn |
| Dec 31, 2021 | 260.49 Mn |
| Sep 30, 2021 | 279.20 Mn |
| Jun 30, 2021 | 297.19 Mn |
| Mar 31, 2021 | 313.61 Mn |
| Dec 31, 2020 | 328.10 Mn |
| Sep 30, 2020 | 125.55 Mn |
| Jun 30, 2020 | -58.79 Mn |
| Mar 31, 2020 | -29.59 Mn |
| Dec 31, 2019 | -20.53 Mn |
| Sep 30, 2019 | -14.36 Mn |